Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research
- PMID: 33673913
- PMCID: PMC7831394
- DOI: 10.1016/j.mayocp.2020.12.006
Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research
Abstract
Objective: To report the Mayo Clinic experience with coronavirus disease 2019 (COVID-19) related to patient outcomes.
Methods: We conducted a retrospective chart review of patients with COVID-19 diagnosed between March 1, 2020, and July 31, 2020, at any of the Mayo Clinic sites. We abstracted pertinent comorbid conditions such as age, sex, body mass index, Charlson Comorbidity Index variables, and treatments received. Factors associated with hospitalization and mortality were assessed in univariate and multivariate models.
Results: A total of 7891 patients with confirmed COVID-19 infection with research authorization on file received care across the Mayo Clinic sites during the study period. Of these, 7217 patients were adults 18 years or older who were analyzed further. A total of 897 (11.4%) patients required hospitalization, and 354 (4.9%) received care in the intensive care unit (ICU). All hospitalized patients were reviewed by a COVID-19 Treatment Review Panel, and 77.5% (695 of 897) of inpatients received a COVID-19-directed therapy. Overall mortality was 1.2% (94 of 7891), with 7.1% (64 of 897) mortality in hospitalized patients and 11.3% (40 of 354) in patients requiring ICU care.
Conclusion: Mayo Clinic outcomes of patients with COVID-19 infection in the ICU, hospital, and community compare favorably with those reported nationally. This likely reflects the impact of interprofessional multidisciplinary team evaluation, effective leveraging of clinical trials and available treatments, deployment of remote monitoring tools, and maintenance of adequate operating capacity to not require surge adjustments. These best practices can help guide other health care systems with the continuing response to the COVID-19 pandemic.
Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Figures



Comment in
-
In reply-Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research.Mayo Clin Proc. 2021 Apr;96(4):1092-1093. doi: 10.1016/j.mayocp.2021.02.005. Epub 2021 Feb 8. Mayo Clin Proc. 2021. PMID: 33814077 Free PMC article. No abstract available.
-
Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research.Mayo Clin Proc. 2021 Apr;96(4):1092. doi: 10.1016/j.mayocp.2021.02.004. Epub 2021 Feb 8. Mayo Clin Proc. 2021. PMID: 33814078 Free PMC article. No abstract available.
Similar articles
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19.JAMA Netw Open. 2020 Dec 1;3(12):e2029058. doi: 10.1001/jamanetworkopen.2020.29058. JAMA Netw Open. 2020. PMID: 33301018 Free PMC article.
-
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394. JAMA. 2020. PMID: 32250385 Free PMC article.
-
Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit.JAMA Netw Open. 2020 Jun 1;3(6):e2012270. doi: 10.1001/jamanetworkopen.2020.12270. JAMA Netw Open. 2020. PMID: 32543702 Free PMC article. Review.
-
Obesity in patients with COVID-19: a systematic review and meta-analysis.Metabolism. 2020 Dec;113:154378. doi: 10.1016/j.metabol.2020.154378. Epub 2020 Sep 28. Metabolism. 2020. PMID: 33002478 Free PMC article.
Cited by
-
Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19.J Prim Care Community Health. 2021 Jan-Dec;12:21501327211019282. doi: 10.1177/21501327211019282. J Prim Care Community Health. 2021. PMID: 34032171 Free PMC article.
-
Avoiding the "Faux Equalizer".Mayo Clin Proc. 2021 Dec;96(12):2963-2965. doi: 10.1016/j.mayocp.2021.08.010. Epub 2021 Oct 30. Mayo Clin Proc. 2021. PMID: 34728058 Free PMC article. No abstract available.
-
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records.PLoS One. 2024 Jul 16;19(7):e0304822. doi: 10.1371/journal.pone.0304822. eCollection 2024. PLoS One. 2024. PMID: 39012863 Free PMC article.
-
PROMIS Scales for Assessment of Persistent Post-COVID Symptoms: A Cross Sectional Study.J Prim Care Community Health. 2021 Jan-Dec;12:21501327211030413. doi: 10.1177/21501327211030413. J Prim Care Community Health. 2021. PMID: 34231395 Free PMC article.
-
Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research.Mayo Clin Proc. 2021 Apr;96(4):1092. doi: 10.1016/j.mayocp.2021.02.004. Epub 2021 Feb 8. Mayo Clin Proc. 2021. PMID: 33814078 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical